Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
A10BK07
|
| gptkbp:brand |
gptkb:Zynquista
|
| gptkbp:CASNumber |
1018899-04-1
|
| gptkbp:developedBy |
gptkb:Lexicon_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C21H23O5S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sotagliflozin
|
| gptkbp:IUPACName |
(2S,3R,4R,5S,6R)-2-(4-ethoxybenzyl)-6-(4-(1-methylethyl)benzyl)-3,4,5-trihydroxy-tetrahydro-2H-pyran-2-yl sulfanyl acetate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
SGLT2 inhibitor
SGLT1 inhibitor |
| gptkbp:molecularWeight |
386.47 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:diabetic_ketoacidosis
urinary tract infection genital mycotic infections |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
gptkb:type_2_diabetes
type 1 diabetes |
| gptkbp:bfsParent |
gptkb:Lexicon_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|